Klupsch, Kristina
Baeriswyl, Vanessa
Scholz, Roland
Dannenberg, Joana
Santimaria, Roger
Senn, David
Kage, Elena
Zumsteg, Adrian
Attinger-Toller, Isabella
von der Bey, Ulrike
König-Friedrich, Susann
Dupuy, Fanny
Lembke, Wibke
Albani, Clara
Wendelspiess, Severin
Dinkel, Lucijana
Saro, Dorina
Hepler, Robert W.
Laszlo, George S.
Gudgeon, Chelsea J.
Bertschinger, Julian
Brack, Simon
Walter, Roland B. http://orcid.org/0000-0002-9268-3341
Funding for this research was provided by:
Leukemia and Lymphoma Society (Scholar in Clinical Research)
Article History
Received: 31 May 2018
Revised: 12 July 2018
Accepted: 7 August 2018
First Online: 11 September 2018
Compliance with ethical standards
:
: KK, VB, RS, JD, RS, DS, EK, AZ, IA-T, UvdB, SK-F, FD, WL, CA, SW, LD, JB, and SB are employees of Covagen AG. DS and RWH are employees of Janssen R&D. RBW received laboratory research grants and/or clinical trial support from Actinium Pharmaceuticals, Inc., Amgen Inc., Amphivena Therapeutics, Inc., Aptevo Therapeutics, Inc., Covagen AG, and Seattle Genetics, Inc.; has ownership interests with Amphivena Therapeutics, Inc.; and is (or has been) a consultant to Amphivena Therapeutics, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Covagen AG, Emergent Biosolutions, Inc. (now Aptevo Therapeutics, Inc.), Pfizer, Inc., and Seattle Genetics, Inc. GSL and CJG declare that they have no conflict of interest.